BRAF and neoplasm: Patients treated with a BRAF inhibitor had a clinically significant prolongation of survival over 13-16 months as a first line therapy [2,3] and rapid tumour regression; however, the majority of them acquires resistance to therapy and relapses very rapidly [4].